linjc16/ctgov huggingface dataset:
Effects of Non-invasive Brain Stimulation in Tobacco Use Disorder

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to determine the effect of non-invasive brain stimulation on craving for tobacco and brain metabolites.

Conditions
-----------------
Tobacco Use Disorder

Intervention / Treatment
-----------------
* Device: Non-invasive brain stimulation (active)
* Device: Non-invasive brain stimulation (sham)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tobacco use disorder (DSM-V) Exclusion Criteria: Other psychiatric disorders Contraindication to non-invasive brain stimulation and MRI

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active<br>Non-invasive brain stimulation (active) | Device: Non-invasive brain stimulation (active)<br>* Non-invasive brain stimulation (active)<br>|
| Placebo Comparator: Sham/Placebo<br>Non-invasive brain stimulation (sham) | Device: Non-invasive brain stimulation (sham)<br>* Non-invasive brain stimulation (sham)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tobacco craving | Subjective craving scale | During experimentation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain metabolites | Magnetic resonance imaging | During experimentation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-invasive brain stimulation, tobacco use disorder, craving
Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6

Study Overview
=================
Brief Summary
-----------------
Randomisation of 72 large rural areas (blocks) into a 2 x 2 trial of six- monthly treatment of all village children aged 1-5 with albendazole(400mg), vitamin A (200000 iu), both or neither. The placebo group get no trial treatment at all and do not receive physical placebos.

Official Title
-----------------
Deworming and Enhanced Vitamin A Supplementation DEVTA Project

Conditions
-----------------
Village Children

Intervention / Treatment
-----------------
* Drug: Vitamin A
* Drug: Albendazole


Participation Criteria
=================
Eligibility Criteria
-----------------
InclusionCriteria: Area of residence Exclusion Criteria: NONE

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vitamin A|nan|
|Drug: Albendazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| childhood mortality rate at age 1-6 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fecal egg counts, plasma retinal, growth, sign of Vitamin A deficiency |  |  |
The International Imaging Registry in Liver Cirrhosis (BAVENO-VI SPSS GROUP).

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to perform a multicentre registry of cirrhotic patients who had been submitted to an imagining technique in recent years (angio-CT scan or abdominal MRI), in order to collect anatomical and clinical information. The main objective will be focused on the study of portosystemic shunts and their relation with portal hypertension. Patient with liver cirrhosis submitted to an abdominal angio-CT scan or a MRI from year 2010 to 2014 will be included in the study. The chosen imaging technique will be angio-CT preferably, but MRI data will also be available. Patients will be identified in every hospital by means of the registry of coded diagnoses and the lists of complementary tests performed. Clinical and radiological data of every patient will be collected. The clinical variables will be obtained from reviewing the patient clinical history. The radiological parameters will be gathered by means of the systematic review of the angio-CT or MRI.

Official Title
-----------------
LARGE SPONTANEOUS PORTOSYSTEMIC SHUNTS (SPSSs) IN PATIENTS WITH LIVER CIRRHOSIS. CLINICAL AND RADIOLOGICAL CHARACTERISTICS.

Conditions
-----------------
Liver Cirrhosis, Portal Hypertension, Hepatic Encephalopathy

Intervention / Treatment
-----------------
* Other: No intervention is studied


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Liver cirrhosis An evaluable imaging test (angio-CT or MRI) performed by any reason in the study period (from January 2010 to December 2014) Exclusion Criteria: Presence of previous surgical shunts Prior liver transplant Neurological or psychiatric disorder that do not permit to establish the diagnosis of hepatic encephalopathy Presence of hepatocellular carcinoma beyond Milan criteria Terminal disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention is studied|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cirrhotic patients with a portosystemic shunt detected by angio-CT scan or MRI |  | 4 years | 
| Number of cirrhotic patients that develop hepatic encephalopathy as a decompensation |  | 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type of portosystemic shunts detected by angio-CT scan or MRI |  | 4 years | 
| Number of cirrhotic patients that develop a decompensation (ascites, variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome) |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Portosystemic Shunt, Hepatic encephalopathy, Portal hypertension, Liver cirrhosis
Evaluation of Mallampati Score Changes in Pregnancy

Study Overview
=================
Brief Summary
-----------------
Pregnant patients mallampati class scores will be examined throughout pregnancy

Detailed Description
-----------------
Photographs of the airway will be taken and compared throughout labor and delivery

Official Title
-----------------
Evaluation of Mallampati Score Changes in Pregnancy

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Procedure: photograph


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant at least 18 years of age Exclusion Criteria: refusal of consent known difficult airway

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: photograph|photograph of airway|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mallampati score changes during pregnancy | mallampati scores classification from 1 to 4 | 40 weeks |
Measurement of Kidney Blood Flow and Oxygen Levels by MRI

Study Overview
=================
Brief Summary
-----------------
Comparison of renal blood flow measurements by PAH clearance and MRI

Detailed Description
-----------------
The traditional measurement of renal blood flow in ml/min involves the collection of multiple blood and urine samples after an infusion of a drug called para-aminohippurate (PAH) is given. In this study, the investigators determine the ability of MRI to estimate renal blood flow. The primary hypothesis is that renal blood flow as measured by PAH clearance is similar to renal blood flow as estimated by MRI. The measurements by PAH clearance and MRI are both performed on the same day.

Official Title
-----------------
MRI for the Non-invasive Determination of Renal Blood Flow and Renal Oxygenation

Conditions
-----------------
Chronic Kidney Disease

Intervention / Treatment
-----------------
* Drug: Furosemide
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In this study, the investigators will enroll 16 men and women aged ≥ 18 years with Stage II - V chronic kidney disease (CKD). In addition, the investigators will enroll 4 subjects with a glomerular filtration rate (GFR) of greater than 60 ml/min who do not have any evidence of CKD. Exclusion Criteria: This study excludes those not suitable for MRI or for the interventional pharmacologic procedures.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: PAH<br>PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide | Other: Placebo<br> <br> |
| Active Comparator: MRI after furosemide<br>After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow | Drug: Furosemide<br>* Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.<br>* Other names: Lasix;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of Renal Blood Flow of the Kidney by the PAH Method | Renal blood flow is estimated by the PAH method. | Renal blood flow is estimated over 1 hour by PAH | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of Regional Blood Oxygenation by MRI | Estimate of renal blood flow by using MRI scans before and after the administration of furosemide | One measure after furosemide (day 1) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI, Renal blood flow, Regional renal blood flow
Reproducibility of Magnetic Resonance Myocardial Salvage Index

Study Overview
=================
Brief Summary
-----------------
The myocardial salvage assessed by using multimodal cardiac magnetic resonance imaging is a rather new technique which can be used as a surrogate endpoint to reduce the sample size in studies comparing different reperfusion strategies in myocardial infarction. As reproducibility of myocardial salvage has not been evaluated appropriately, we aim to scan 20 patients on 2 subsequent days to evaluate reproducibility of myocardial salvage index.

Official Title
-----------------
Reproducibility of Myocardial Salvage Index in Acute Myocardial Infarction by Cardiac Magnetic Resonance Imaging

Conditions
-----------------
Myocardial Infarction

Intervention / Treatment
-----------------
* Device: second magnetic resonance imaging scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ST-elevation myocardial infarction Primary percutaneous coronary intervention Exclusion Criteria: Contraindications for magnetic resonance imaging

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute myocardial infarction patients<br> | Device: second magnetic resonance imaging scan<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Myocardial salvage index reproducibility |  | 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| infarct size reproducibility |  | 2 days | 
| area at risk reproducibility |  | 2 days | 
| microvascular obstruction reproducibility |  | 2 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
reproducibility, contrast agent, magnetic resonance imaging, infarct size, myocardial salvage index, myocardial salvage assessment
Visiobiane Anti-age Effects on Vision Parameters

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the benefits of Visiobiane Anti-age dietary supplement on macular pigment optical density, contrast sensibility and visual acuity. Additionally, the study would like to evaluate seric variations of carotenoids and the total antioxydant capacity.

Detailed Description
-----------------
Visiobiane study is a randomized trial of 30 participants designed to assess the effects of oral supplementation of macular xanthophylls (lutein and zeaxanthin) and omega-3 LCPUFAs for the eyes protection. The study will enroll healthy participants aged 45 to 55 years. 15 subjects will be assigned in placebo group and 15 in experimetal group (Visiobiane anti-age). They will be supplemented for 24 weeks

Official Title
-----------------
Study of the Effects of Visiobiane Anti-age Dietary Supplement on Macular Pigment Optical Density, Contrast Sensibility and Visual Acuity

Conditions
-----------------
Macular Pigment Optical Density

Intervention / Treatment
-----------------
* Drug: lutein
* Drug: DHA
* Drug: vitamins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy caucasian men age : 45-55 BMI < 25 Exclusion Criteria: non healthy retinian and/or visual anomaly Ocular media not clear enough to allow good fundus photography

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: lutein|nan|
|Drug: DHA|nan|
|Drug: vitamins|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| macular pigment optical density |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| contrast sensibility |  |  | 
| visual acuity |  |  | 
| seric carotenoids concentrations |  |  | 
| total antioxidant capacity |  |  | 
| influence of SR-B1 genetic polimorphism |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
visual caracteristics, macular pigment optical density, visual acuity, contrast sensibility, lutein, docosahexaenoic acid (DHA)
Screening for Fabry Disease Among Young Stroke Patients in an Israeli Stroke Clinic

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the incidence of Fabry Disease in young stroke patients in an Israeli stroke clinic.

Conditions
-----------------
Fabry Disease in the Young Stroke

Intervention / Treatment
-----------------
* Other: blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of stoke or TIA Time period within last 5 years - Exclusion Criteria: Known diagnosis of stroke or index event due to trauma -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| positive screening of fabry disease |  | past 5 years |
How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

Study Overview
=================
Brief Summary
-----------------
The study will seek to determine whether there is a corresponding deficit in school performance for teenagers with NF1. Secondly, the study seeks to explore the issue of self-esteem in teenagers with NF1.

Official Title
-----------------
Cognitive Impairments, Self-Esteem & Academic Performance in Teenagers With Neurofibromatosis Type 1

Conditions
-----------------
Neurofibromatosis Type 1

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Neurofibromatosis Type 1 Exclusion Criteria: Neurofibromatosis Type 2 Schwannomatosis

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NF1 teenagers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of effect on self-esteem evidenced by self-esteem scores |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neurofibromatosis
Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.

Official Title
-----------------
An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Amprenavir/ritonavir
* Drug: Saquinavir/ritonavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Subject must remain on current antiretroviral therapy during screening until a new regimen is initiated. Subject demonstrates reduced susceptibility to lopinavir. Subject's two most recent viral loads obtained after at least 16 weeks of lopinavir/ritonavir therapy, and while still on Kaletra therapy must be at least 1,000 copies/mL. The Kaletra regimen must be the subject's second PI containing regimen and must not contain any other PIs. Subject is at least 18 years of age. Subject has not been treated for an active opportunistic infection within 30 days of screening. Exclusion: Subject has a history of active substance abuse or psychiatric illness that could preclude compliance to the protocol. Female subject pregnant or lactating. Use of an Investigational drug within 30 days prior to the initiation of drug dosing. Subject is receiving systemic chemotherapy. Subject has a history of acute or chronic pancreatitis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Amprenavir/ritonavir|nan|
|Drug: Saquinavir/ritonavir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, treatment experienced